8-K: Scilex Invests $150M in Datavault AI with Bitcoin

Scilex Holding Company announced a $150 million strategic investment in Datavault AI Inc., utilizing Bitcoin to acquire common stock and warrants, aiming to capitalize on the biotech data monetization market.

Summary

• Scilex Holding Company (SCLX) has made a strategic investment of $150 million in Datavault AI Inc. (DVLT).
• The investment involves the purchase of 15.0 million shares of Datavault common stock and a pre-funded warrant to acquire an additional 263,914,094 shares of Datavault common stock.
• The initial tranche of 15.0 million shares was acquired at an effective purchase price of $0.5378 per share, paid in Bitcoin (BTC) on September 26, 2025.
• The remaining approximately $141.9 million for the pre-funded warrant will be paid in BTC upon Datavault obtaining stockholder approval for the issuance of shares exceeding 19.99% of its outstanding stock and an increase in authorized common stock to up to 1.5 billion shares.
• Scilex will have the right to nominate two directors to Datavault's board if it maintains at least 10% beneficial ownership, or one director if it holds between 5% and 10%.
• The investment aims to provide growth capital for Datavault to accelerate its supercomputing infrastructure, expand data exchanges, and unlock new revenue streams, particularly in the biotech data monetization market.
• Scilex intends to leverage its biotech expertise to create a potential marketplace for tokenized Real-World Assets (RWA) in the biotech and pharmaceutical industry.
• Datavault is required to seek stockholder approval for the second tranche within 75 days of the initial closing, with provisions for subsequent meetings if approval is not obtained.
• Scilex will be reimbursed $300,000 by Datavault for legal fees and expenses incurred in connection with the transaction.
• Scilex has agreed to a lock-up on the Bitcoin used for the initial subscription amount until the additional closing date.

Sentiment

Score: 7

Explanation: The strategic investment in Datavault AI is a positive move for Scilex, offering diversification into high-growth tech sectors and potential for significant returns. The board representation and the focus on biotech data monetization are strong points. However, the contingency on Datavault's stockholder approval and the lock-up on Bitcoin introduce some uncertainty and potential delays, preventing a higher score.

Positives

• Strategic investment in Datavault AI positions Scilex to capitalize on the growing biotech data monetization market, projected to reach $30-50 billion by 2024.
• The investment provides Scilex with significant equity ownership and board representation rights in Datavault AI, allowing for strategic influence.
• Scilex's expertise in the biotech and pharmaceutical sector can be leveraged to guide Datavault and potentially create a marketplace for tokenized Real-World Assets (RWA).
• The use of Bitcoin for the investment demonstrates a forward-thinking approach to digital assets and potentially offers advantages in transaction efficiency.
• Scilex will be reimbursed $300,000 for legal fees and expenses incurred in connection with the transaction.

Negatives

• The full investment and issuance of the pre-funded warrant shares are contingent on Datavault's stockholder approval, which introduces a degree of uncertainty and potential delay.
• The investment ties up $150 million of Scilex's capital, with a significant portion contingent on future events.
• The lock-up on the Bitcoin used for the initial subscription amount until the additional closing date restricts Scilex's liquidity for that portion of the investment.
• The transaction involves a company (Datavault AI) whose primary business is outside Scilex's core focus of non-opioid pain management, potentially diversifying risk but also introducing new operational complexities.

Risks

• General economic, political, and business conditions could adversely affect the transaction's benefits.
• Datavault's ability to obtain stockholder approval for the second tranche of the investment is not guaranteed, potentially delaying or preventing the full realization of the investment.
• The anticipated benefits of the transaction, including future financial and operating results, may not be achieved.
• Legal proceedings could be instituted against the parties regarding the transactions.
• The transaction could disrupt current plans and operations for both Scilex and Datavault.
• Risks related to the development and successful marketing of Datavault's products.
• Uncertainty regarding the regulatory pathway for Scilex's product candidates and their commercialization.
• Overestimation of target patient populations, their willingness to try new therapies, and physicians' willingness to prescribe them.
• Prior clinical trial results for Scilex's product candidates may not be replicated.
• Regulatory and intellectual property risks for both companies.
• Failure to realize the anticipated benefits of the transactions contemplated with Datavault.
• The market price of Datavault's publicly traded securities could be negatively impacted by various factors, including future open market or derivative transactions by the Purchaser.

Future Outlook

Scilex anticipates leveraging Datavault's AI and supercomputing technologies to create a marketplace for tokenized Real-World Assets (RWA) in the biotech and pharmaceutical industry, aiming to capture growth in the biotech data monetization market. The full investment is contingent on Datavault stockholder approval, which is expected to be sought within 75 days of the initial closing.

Management Comments

• "Datavault's cutting-edge technologies align perfectly with the biotech sector's need for advanced data analytics, AI-driven insights, and super computing power. This investment reflects our belief in Datavault's ability to transform markets where trust and precision are critical." Henry Ji, Ph.D., CEO, President and Chairman of the Board of Scilex Holding Company.
• "Biotech is a market we know well, and we will help guide Datavault to maximum revenue generation in our sector while Datavault expands across the global economy. With our resources and their patented technology, we see an incredible opportunity to drive real global impact together." Henry Ji, Ph.D.

Industry Context

This investment positions Scilex, primarily a non-opioid pain management company, to diversify into the rapidly growing fields of AI, supercomputing, and data monetization, particularly within the life sciences and biotech sectors. The move aligns with broader industry trends of digital transformation, data-driven insights, and the increasing value of real-world data in healthcare and pharmaceuticals. Datavault's focus on Web 3.0, blockchain-secured data trading, and AI-driven analytics addresses critical needs for data integrity and monetization in these high-growth markets.

Comparison to Industry Standards

• The global AI market is projected to reach $1.8 trillion by 2030, indicating a significant growth opportunity that Datavault AI aims to capture.
• The life sciences analytics market, estimated at $35.69 billion in 2024 with an 11.4% CAGR through 2030, highlights the specific sector Datavault AI targets for growth.
• The biotech data monetization market is expected to reach $30-50 billion by 2024, suggesting a substantial addressable market for Scilex's proposed RWA marketplace.
• The investment in AI and blockchain technology for data monetization is consistent with emerging trends in the pharmaceutical and biotech industries, where data integrity, security, and efficient exchange are becoming paramount.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders (Scilex): Potential for long-term value creation through diversification into high-growth AI/data monetization sectors and strategic influence over Datavault. However, the investment ties up capital and introduces new risks associated with a non-core business.
• Shareholders (Datavault): Significant capital infusion ($150 million) for growth, potentially accelerating business expansion and innovation. Dilution from the issuance of new shares, subject to stockholder approval.
• Employees (Datavault): Potential for accelerated growth, expansion, and new opportunities due to increased capital and strategic guidance from Scilex.
• Customers (Datavault): Potential for enhanced products and services due to accelerated supercomputing infrastructure and data exchange expansion.

Next Steps

• Datavault AI Inc. to file a preliminary proxy statement with the SEC within 25 days of September 26, 2025, to obtain stockholder approval.
• Datavault AI Inc. to hold an annual or special meeting of its stockholders no later than 75 days after September 26, 2025, to obtain stockholder approval for the issuance of the pre-funded warrant shares and an increase in authorized common stock.
• If stockholder approval is not obtained, Datavault AI Inc. will hold additional stockholder meetings every fourth month thereafter until approval is secured.
• Scilex Holding Company to receive the pre-funded warrant and pay the additional subscription amount in Bitcoin following Datavault's stockholder approval.
• Scilex Holding Company to apply to list all of the acquired Datavault shares and pre-funded warrant shares on the Nasdaq Stock Market LLC.
• Scilex Holding Company to potentially designate directors to Datavault AI Inc.'s Board of Directors based on its beneficial ownership percentage.

Key Dates

Recommendation

The strategic investment in Datavault AI presents a compelling long-term growth opportunity for Scilex, diversifying its portfolio into high-growth AI and biotech data monetization sectors. The potential for significant returns and strategic influence through board representation are positive. However, the investment is substantial, and the full realization is contingent on Datavault's stockholder approval, which introduces execution risk and potential delays. The use of Bitcoin and the lock-up period also add layers of complexity. Given these factors, a 'hold' recommendation is appropriate, advising investors to monitor the progress of Datavault's stockholder approval and the integration of Scilex's strategic guidance before making further investment decisions.

Keywords

Biotech Investment, Datavault AI, Bitcoin Investment, Strategic Partnership, AI Data Analytics, Real-World Assets, RWA Tokenization, Non-Opioid Pain Management, SEC Filing, SCLX, DVLT, Warrants, Stockholder Approval, Corporate Governance